Program
capivasertib
Also written as “Capivasertib”, “AZD5363” and “Intermittent dosing of AZD5363”.
Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Triple Negative Breast Neoplasms · Hematologic Neoplasms, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 239 open or running | phase 3since May 20, 2019 | Oct 21, 2010 | Nov 1, 2027phase 3 · NCT04862663 |
Also a collaborator on its studies: apices-soluciones-s-l, parexel and quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Oct 21, 2010.
- Jul 9, 2020Phase 3 study in Prostatic NeoplasmsNCT04493853 · 1,012 enrolled · United States, Argentina, Australia and more
- Dec 15, 2020Phase 1 study in Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)NCT04712396 · 11 enrolled · Germany
- Jan 15, 2021Phase 1 study in Advanced Solid TumoursNCT04742036 · 16 enrolled · China
- Mar 17, 2021Phase 3 study in Locally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663 · 893 enrolled · United States, Argentina, Australia and more
- Jun 28, 2021Phase 1 study in Hematologic NeoplasmsNCT04944771 · 48 enrolled · Germany
- Jul 1, 2021Phase 1 study in Solid TumourNCT04958226 · 21 enrolled · United States
- Jul 19, 2021Phase 2 study in RecurrenceNCT05008055 · 30 enrolled · United States, Canada, Denmark and more
- Mar 18, 2022Phase 3 study in Prostatic NeoplasmsNCT05348577 · 1,035 enrolled · United States, Australia, Belgium and more
- Apr 11, 2022Phase 1 study in Healthy VolunteerNCT05419401 · 7 enrolled · United Kingdom
- Sep 9, 2024Phase 3 study in Breast NeoplasmsNCT06635447 · 293 enrolled · China
- Nov 28, 2024Phase 3 study in Breast NeoplasmsNCT06764186 · 101 enrolled · Spain
- Jul 17, 2025Phase 1 study in Healthy ParticipantsNCT07088913 · 20 enrolled · United States
- Nov 17, 2025Phase 1 study in Healthy ParticipantsNCT07241065 · 42 enrolled · Germany
- Jan 7, 2026Phase 1 study in Moderate Hepatic ImpairmentNCT07343960 · 20 planned · United States
Ahead
- Nov 11, 2026Primary completion: phase 1 study in Moderate Hepatic ImpairmentNCT07343960
- Nov 1, 2027Primary completion: phase 3 study in Locally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663
- Nov 30, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06764186
TargetBeta
“Serine/threonine-protein kinase AKT inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07343960Moderate Hepatic Impairment · United States | 1 | Recruiting | Nov 11, 2026 | 20 |
| NCT07241065Healthy Participants · Germany | 1 | Completed | Jul 20, 2026 | 42 |
| NCT07088913Healthy Participants · United States | 1 | Completed | Feb 20, 2026 | 20 |
| NCT06764186Breast Neoplasms · Spain | 3 | Active, not recruiting | Nov 30, 2027 | 101 |
| NCT06635447Breast Neoplasms · China | 3 | Active, not recruiting | Oct 31, 2026 | 293 |
| NCT05419401Healthy Volunteer · United Kingdom | 1 | Completed | Jul 12, 2022 | 7 |
| NCT05348577Prostatic Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Mar 4, 2026 | 1,035 |
| NCT05008055Recurrence · United States, Canada, Denmark and more | 2 | Completed | Aug 22, 2023 | 30 |
| NCT04958226Solid Tumour · United States | 1 | Completed | Feb 6, 2023 | 21 |
| NCT04944771Hematologic Neoplasms · Germany | 1 | Completed | May 4, 2022 | 48 |
| NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 1, 2027 | 893 |
| NCT04742036Advanced Solid Tumours · China | 1 | Completed | Jul 29, 2022 | 16 |
| NCT04712396Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) · Germany | 1 | Completed | Mar 25, 2021 | 11 |
| NCT04493853Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 7, 2024 | 1,012 |
| NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 9, 2023 | 818 |
| NCT04087174Prostatic Neoplasms · United States, Spain | 1 | Completed | Jun 22, 2021 | 27 |
| NCT03997123Triple Negative Breast Neoplasms · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Mar 16, 2026 | 923 |
| NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more | 2 | Active, not recruiting | Nov 29, 2024 | 243 |
| NCT01895946Advanced Solid Malignancy, · Netherlands, United Kingdom | 1 | Completed | Feb 2015 | 33 |
| NCT01692262Prostatic Neoplasms · United States, United Kingdom | 1 | Completed | Jun 2014 | 59 |
| NCT01625286Breast Neoplasms · Bulgaria, Canada, Czechia and more | 2 | Completed | Jan 28, 2017 | 148 |
| NCT01353781Advanced Solid Malignancy · Japan | 1 | Completed | Jul 2014 | 39 |
| NCT01226316Breast Neoplasms · United States, Canada, Denmark and more | 1 | Completed | Apr 26, 2019 | 285 |
How it is read
Names in the registry
- “Capivasertib”, 16 entries
- “AZD5363”, 7 entries
- “Intermittent dosing of AZD5363”, 3 entries
- “AZD5363 when combined with weekly paclitaxel.”, 2 entries
- “capivasertib”, 1 entry
Codes read as this program: AZD5363.
Conditions, from the studies’ own filings
- Breast Neoplasms, 7 studies
- Prostatic Neoplasms, 4 studies
- Triple Negative Breast Neoplasms, 2 studies
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.